20^th Asia-Pacific Pharma Congress April 22-23, 2019 Tokyo, Japan

Biography:

Jeremy Choo Tze Yang has graduated with a Bachelor of Science from University of Melbourne with a major in Medical Microbiology in 2003. After which, he went on to obtain a professional degree, Master of Pharmacy from Murdoch University in August 2007. After graduation, he tutored and demonstrated various aspects of biomedical sciences including pharmacology to both local and overseas tertiary institutions (Anderson Junior College, Temasek Polytechnic, Singapore Institute of Science, Raffles Education Corporation and Edith Cowan University in Perth). As a Registered and Practicing Pharmacist in Singapore (Airport Pharmacy, THK Hospital, NHGP, Guardian) and Australia, he was certified nationally by WSQ to be curriculum developer, trainer and assessor, leadership and people management,as well as having professional knowledge in medication management review (Australia), ambulatory care, smoking cessation, counselling (Singapore), as well asanticoagulation studies (USA). Furthermore, he has additional certification in Career Coaching and Healthcare Management, as well as having a strong belief in lifelong learning and a fascination with infectious agents. With a keen research interest in medication adherence and pharmacy automation, he had collaborated with Epilepsy Care Group, KTPH, i3 Precision and Guardian Health and Beauty to work on these projects. Moreover, he has a keen interest in stage hosting and radio production

Abstract:

Recent pedagogical approaches within the field of applied sciences incorporate problem-based learning and hands-on training. Republic Polytechnic’s School of Applied Sciences (SAS) in collaboration with the School of Engineeringand the School of Info COMM, has developed RPMED, a user-friendly and efficient dispensing software as a learning platformto hone student’s clinical and dispensing skills. By embracing new technologies and automation such as RPMED, studentswill be inculcated with the values and principles of pharmaceutical care such as medication safety, patient care continuum,dispensing process efficiencies and documentation procedures.

Methods: Developing RPMED requires a system of IT improvements. First, the students review current dispensing softwareissues raised by previous development teams. Next, students from SAS address these issues in collaboration with teams from the School of Infocomm. The third phase involves enhancing and implementing new features in RPMED. Lastly, end usersfeedback surveys are prepared, designed, conducted and reviewed by SAS students to determine RPMED software usabilityand future enhancements.

Results: Three improvement processes within RPMED had been identified and implemented: A barcode system, a druginteraction matrix and drug imaging. Implementing barcode systems on pharmaceutical products reduces medicationselection errors, thereby improving dispensing accuracy and efficiency. A drug interaction matrix improves medication safety by allowing concurrent checks for drug interactions when new medications are added to patients’ drug chart. A pop-up alertwill appear when drug interactions are found. Drug imaging incorporates reference images within the software for quick and accurate identification and selection of medicines. End users feedback surveys showed widespread acceptance and usability among students.Conclusion: Developing and using RPMED allows students to appreciate the verisimilitudes with commercially available dispensing software. The system of checks and balances within RPMED allow students to gain insight into the complexities involved in IT use within pharmaceutical care.

Biography:

Sonia Shastri is currently a PhD candidate at University of Tasmania, Australia. She holds Master’s degree in Pharmaceutical Science from the University of Tasmania and Bachelor of Pharmacy degree from Kurukshetra University, India. Her research focuses on investigating the efficacy of antioxidant drug in ulcerative colitis.

Abstract:

Idebenone, short chain quinone, has been described as a potent antioxidant and mitochondrial electron donor. Itstherapeutical potential has been described extensively in numerous pathological conditions ranging from neurodegenerative,neuromuscular to diverse metabolic conditions. There is also some emerging evidence that idebenone has some antiinflammatoryactivity. Oxidative stress is one of the key players of the inflammatory cascade responsible for the initiationof Ulcerative Colitis (UC). Therefore, we investigated the anti-oxidative and anti-inflammatory properties of idebenone indextran sodium sulfate (DSS)-induced mouse model of acute colitis. Acute colitis was introduced in female C57BL/6J mice by administering 2.5% of DSS in autoclaved water continuously for 7 days. Changes in body weight, Disease Activity Index (DAI),colon length and histopathological parameters were evaluated and scored. Colonic contents of Malondialdehyde (MDA), amarker of lipid peroxidation were also examined as a parameter of disease-associated redox state. Protein expression of theoxidative stress induced redox factor NAD(P)H dehydrogenase quinone-1 (NQO-1) was determined by western blot, while the levels of various pro-inflammatory cytokines were quantified using Bio-Plex assay. Oral administration of idebenone at a doseof 200 mg/kg body weight significantly against body weight loss, improved DAI, colon length and histopathology. Idebenone also significantly reduced MDA content as well as pro- inflammatory cytokine levels such as IL-1α, TNF-α, G-CSF, GM-CSF,MIP-1α, MIP-1β, RANTES and EOTAXIN; furthermore, idebenone upregulated NQO1 protein levels. These results suggest that idebenone could represent a promising therapeutic strategy to interfere with disease pathology in UC by inducing antioxidative and anti-inflammatory pathways.

Biography:

Takahiro Iwamiya has completed his PhD from Tokyo Women’s Medical University and Project Research Associate studies from Institute for Advanced Biosciences, Keio University. He is the Co-Founder & Co-CEO of Metcela Inc. He has published three patents and has been developing novel cell therapy products for heart failure patients.

Abstract:

Cardiac fibroblasts are interstitial cells showing substantial self-duplication ability and having a critical role in heart function through interactions with the myocardial compartment. Recently, they have been extensively used for creating functional bioengineered cardiac tissues and are considered attractive candidates for cell-based therapies. However, both in health and disease, cardiac fibroblasts present heterogeneous characteristics according to the development stage of the heart and the associated molecular mechanisms leading to the improvement of tissue properties are not fully understood. Here we show thata specific type of human cardiac fibroblasts expressing VCAM-1 (VCFs) can stimulate human cardiomyocyte proliferationin vitro and that both human and rat cells allow substantially improved recovery of heart function after surgically inducedischemic injury in vivo. One week after ischemia-reperfusion injury, rats received VCFs or medium by injections in theinfarcted area. Eighteen (18) weeks after injections, echocardiography revealed an improvement of Left Ventricular Ejection Fraction (LVEF) by 32.6% in rats having received VCFs compared to controls. Moreover, systolic and diastolic functions in rats injected with VCFs or with cardiomyocytes show no significant differences. These results suggest a direct effect of fibroblasts on resident myocardial cells. Overall, these findings show that VCFs have a significant therapeutic potential making themadvantageous for cost-effective cell-based therapy for heart failure linked to ischemic diseases.

Biography:

Abstract:

Biography:

Sayantani Dasgupta is currently working as an Associate Director Customer Engagement and Strategy in MSD based in Tokyo. She has spent over 20 years in the pharmaceutical and healthcare sector in both global and emerging markets in Switzerland, Germany, India, etc. Her passion is to drive customer centricity and enable commercialization of life saving therapies to the right patients at the right time.

Abstract: